Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52
Guggenheim analyst Michael Schmidt maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $45 to $52.
Read original at benzingaStocks · News reference
Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55
Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $52 to $55.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 4:08 PM
- Checked
- Aug 17, 2026, 4:08 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cogent Biosciences Files Prospectus for At-The-Market Offering Of Up To $400M In Common Stock
Up to $400,000,000COMMON STOCKWe have entered into a Sales Agreement with Guggenheim Securities, LLC ("Guggenheim Securities"), dated May 6, 2022, as amended by that certain Amendment No. 1 to Sales Agreement,
Read original at benzinga8-K filing — Cogent Biosciences, Inc. (COGT)
Filed: 2026-08-10 AccNo: 0001193125-26-342695 Size: 155 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar